Advances in Personalized Therapy for Breast Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 5274
Special Issue Editor
Special Issue Information
Dear Colleagues,
For many years, systemic therapy for both early and advanced breast cancer was largely determined by categorizing the disease into four subtypes: luminal A, luminal B, Her2-positive or triple negative. More recent research has enriched our understanding of the biology of breast cancer, and we now understand that, rather than clearly defined subtypes, it may be better described as a continuum. We have access to therapies directed at “Her-2 low” and “Her-2 ultra-low” breast cancer, as well as therapies directed at a host of other targets, including PIK3, CDK4/6 and germline BRCA mutations. Newer treatments are also under investigation, including immuno-oncolytic virus drugs, histone deacetylase inhibitors and combinatorial therapy such as holokiol and rapamycin. As patients and oncologists navigate the ever-changing landscape of therapeutic options, we require efficient and robust strategies to identify and test for the presence or absence of drug targets and resistance mechanisms. While significant advances in systemic therapeutic options have been achieved over the past decade, our ability to identify ‘the right drug for the right patient at the right time’ is lagging. In this Special Issue, we will review the newest targeted therapies and the challenges in accessing them for individual patients in the age of personalized medicine.
We welcome areas that may include (but are not limited to) the following: articles, reviews, case reports, communications, etc.
I look forward to receiving your contributions.
Dr. Erin Powell
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- personalized
- targeted therapy
- target
- subtype
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.